283 related articles for article (PubMed ID: 34733154)
1. Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients.
Liu J; Li Z; Zhang W; Lu H; Sun Z; Wang G; Han X
Front Pharmacol; 2021; 12():709060. PubMed ID: 34733154
[No Abstract] [Full Text] [Related]
2. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
Wei F; Huang Q; He J; Luo L; Zeng Y
Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
[TBL] [Abstract][Full Text] [Related]
3. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma.
Wu J; Zeng J; Wang H; Huo Z; Hou X; He D
Front Oncol; 2023; 13():1244341. PubMed ID: 37916160
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.
You R; Xu Q; Wang Q; Zhang Q; Zhou W; Cao C; Huang X; Ji H; Lv P; Jiang H; Lu Y; Jin Y; Li Y; Cheng L; Wang W; Xu H; Zhu X; Yin G
Front Oncol; 2022; 12():816198. PubMed ID: 35982962
[TBL] [Abstract][Full Text] [Related]
6. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
Front Oncol; 2021; 11():835889. PubMed ID: 35174073
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis.
Xian F; Song XW; Bie J; Zhao CX; Zhang GJ; Xu GH
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):687-701. PubMed ID: 38305611
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.
Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.
Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
Can J Gastroenterol Hepatol; 2022; 2022():7982118. PubMed ID: 35586608
[TBL] [Abstract][Full Text] [Related]
13. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
14. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery.
Wang X; Cao W; Qiu Y; Ji H; Yuan J; Wu W; Liu F; Feng L; Ding R; Li X; Tao K
Front Oncol; 2023; 13():1174999. PubMed ID: 38162488
[TBL] [Abstract][Full Text] [Related]
16. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
[No Abstract] [Full Text] [Related]
17. TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm).
Xiang Z; Li G; Mu L; Wang H; Zhou C; Yan H; Huang M
Technol Cancer Res Treat; 2023; 22():15330338231200320. PubMed ID: 37723998
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study.
Sun B; Zhang L; Sun T; Ren Y; Cao Y; Zhang W; Zhu L; Guo Y; Gui Y; Liu F; Chen L; Xiong F; Zheng C
Front Oncol; 2022; 12():982948. PubMed ID: 36172158
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D; Liu S; Cheng C; Xu L; Zhao P
Medicine (Baltimore); 2023 Sep; 102(35):e34811. PubMed ID: 37657057
[TBL] [Abstract][Full Text] [Related]
20. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
